Company / Financials
Sunshine Biopharma Inc. Financials
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$34.9M
FY2025 · +44.7% YoY
Net Income
-$5.1M
FY2025 · -13.9% YoY
Profit Margin
-14.7%
FY2025 · net income / revenue
ROE
-21.9%
FY2025 · return on equity
Total Assets
$30.1M
FY2025
Total Debt
-
FY2025
Equity
$23.5M
FY2025
ROA
-17.1%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$34.9M+44.7% YoYNet Income HistoryProfit after all expenses and taxes-$5.1M-13.9% YoYGross Profit HistoryRevenue minus cost of goods sold$10.7M+27.9% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$24.2M+53.6% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$5.8M-21.5% YoYSG&A Expense HistorySelling, general, and administrative expenses$16.5M+25.6% YoYR&D Expense HistoryResearch and development spending$933.9K-49.7% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense-$234.9K-159.4% YoYEPS (Basic) HistoryBasic earnings per share-$7.32+97.9% YoY